INS and type 1 diabetes mellitus: In patients with type 1 diabetes, adjunctive therapy with SGLT2is may reduce total insulin doses and increase ketoacidosis events because of elevated ketone levels when low doses of insulin are insufficient to inhibit lipolysis in surrounding adipose tissues [9].